Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

Product information

CAS Number: 1440964-89-5

Molecular Weight: 424.38

Formula: C20H15F3N8

Chemical Name: 5-{[6-(1-cyclopropyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]difluoromethyl}-6-fluoro-2-methyl-2H-indazole

Smiles: CN1C=C2C=C(C(F)=CC2=N1)C(F)(F)C1=NN=C2C=CC(=NN21)C1=CN(N=C1)C1CC1

InChiKey: QHXLXUIZUCJRKV-UHFFFAOYSA-N

InChi: InChI=1S/C20H15F3N8/c1-29-9-11-6-14(15(21)7-17(11)27-29)20(22,23)19-26-25-18-5-4-16(28-31(18)19)12-8-24-30(10-12)13-2-3-13/h4-10,13H,2-3H2,1H3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (117.82 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Bozitinib (PLB-1001) (30 μM; 6 hours) inhibits the phosphorylation of MET and STAT3, has a robust inhibitory effect of PLB-1001 on MET and its downstream signaling pathways.

Products are for research use only. Not for human use.